Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Dasatinib |
| Synonyms | |
| Therapy Description |
Sprycel (dasatinib) is an inhibitor of the SRC-family of protein kinases, BCR-ABL, and ABL, and has additional activity against other kinases including KIT, DDR1/2, PDGFRA/B, and EPHA2, which prevents cell growth (PMID: 25709401, PMID: 25284748, PMID: 18797457, PMID: 23942795). Sprycel (dasatinib) is FDA approved for both Philadelphia chromosome positive adult and pediatric chronic myelogenous leukemia and adult acute lymphoblastic leukemia (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Dasatinib | Sprycel | BMS-354825 | ABL Inhibitor (pan) 8 BCR-ABL Inhibitor 27 BTK inhibitor 24 CSF1R Inhibitor 25 DDR1 Inhibitor 8 DDR2 inhibitor 7 KIT Inhibitor 51 PDGFR Inhibitor (Pan) 27 SRC Inhibitor 29 TNK2 Inhibitor 6 | Sprycel (dasatinib) is an inhibitor of the SRC-family of protein kinases, BCR-ABL, and ABL, and has additional activity against other kinases including KIT, DDR1/2, PDGFRA/B, and EPHA2, which prevents cell growth (PMID: 25709401, PMID: 25284748, PMID: 18797457, PMID: 23942795). Sprycel (dasatinib) is FDA approved for both Philadelphia chromosome positive adult and pediatric chronic myelogenous leukemia and adult acute lymphoblastic leukemia (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| Unknown unknown | alveolar soft part sarcoma | not applicable | Dasatinib | Phase II | Actionable | In a Phase II trial, patients with alveolar soft part sarcoma demonstrated a median progression free survival of 11 months and one patient demonstrated an objective tumor response when treated with Sprycel (dasatinib) (PMID: 27696380). | 27696380 |
| Unknown unknown | gastrointestinal stromal tumor | not applicable | Dasatinib | Phase 0 | Actionable | In a clinical trial, Sprycel (dasatinib) treatment resulted in a 6-month progression-free survival (PFS) rate of 29% (n=48), median PFS of 2.9 months, median overall survival of 19 months, and partial response in 25% (12/48) of patients with Gleevec (imatinib)-resistant gastrointestinal stromal tumor (PMID: 29710216). | 29710216 |
| DDR2 L239R DDR2 T654M | lung squamous cell carcinoma | decreased response | Dasatinib | Preclinical | Actionable | In a preclinical study, expression of DDR2 T654M in lung squamous cell cancer cells harboring DDR2 L239R resulted in decreased sensitivity to Sprycel (dasatinib) in culture (PMID: 22328973). | 22328973 |
| DDR2 I638F DDR2 T654M | lung squamous cell carcinoma | decreased response | Dasatinib | Preclinical | Actionable | In a preclinical study, expression of DDR2 T654M in lung squamous cell cancer cells harboring DDR2 I638F resulted in decreased sensitivity to Sprycel (dasatinib) in culture (PMID: 22328973). | 22328973 |
| KIT T670I | melanoma | resistant | Dasatinib | Preclinical | Actionable | In a preclinical study, melanoma cells expressing KIT T670I demonstrated resistance to treatment with Sprycel (dasatinib) (PMID: 23582185, PMID: 25594040). | 23582185 25594040 |
| DDR2 L239R | Advanced Solid Tumor | sensitive | Dasatinib | Preclinical | Actionable | In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 L239R in culture (PMID: 22328973). | 22328973 |
| CSF3R T618I | hematologic cancer | predicted - resistant | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed hematologic cells expressing CSF3R T618I demonstrated resistance to treatment with Sprycel (dasatinib) in culture (PMID: 28031554). | 28031554 |
| BRAF G466V | lung non-small cell carcinoma | sensitive | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sprycel (dasatinib) induced apoptosis in non-small cell lung cancer cells expressing BRAF G466V in culture (PMID: 22649091). | 22649091 |
| ETV6 - ABL1 | myeloid neoplasm | predicted - sensitive | Dasatinib | Case Reports/Case Series | Actionable | In a clinical study, a patient with a myeloid neoplasm harboring ETV6-ABL1 demonstrated a complete molecular response after being treated with Sprycel (dasatinb) for 18 months (PMID: 32279331). | 32279331 |
| Unknown unknown | malignant peripheral nerve sheath tumor | not applicable | Dasatinib | Phase II | Actionable | In a Phase II clinical trial, a trial arm assessing Sprycel (dasatinib) in patients with malignant peripheral nerve sheath tumors (n=14) was suspended due to lack of drug activity (PMID: 26710211). | 26710211 |
| ARID1A mutant | ovarian clear cell carcinoma | sensitive | Dasatinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Sprycel (dasatinib) resulted in decreased cell growth of ovarian clear cell carcinoma (OCCC) cells harboring an ARID1A mutation in culture and anti-tumor activity in cell line xenograft models of OCCC (PMID: 27364904). | 27364904 |
| Unknown unknown | osteosarcoma | not applicable | Dasatinib | Phase II | Actionable | In a Phase II clinical trial, a trial arm assessing Sprycel (dasatinib) in osteosarcoma patients (n=46) was suspended due to lack of drug activity (PMID: 26710211). | 26710211 |
| DDR2 G505S | Advanced Solid Tumor | sensitive | Dasatinib | Preclinical | Actionable | In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 G505S in culture (PMID: 22328973). | 22328973 |
| CSF3R T618I CSF3R Q741* | hematologic cancer | predicted - resistant | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed hematologic cells co-expressing CSF3R T618I and CSF3R Q741* were resistant to treatment with Sprycel (dasatinib) in culture (PMID: 28031554). | 28031554 |
| DDR2 I638F | lung squamous cell carcinoma | sensitive | Dasatinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Sprycel (dasatinib) inhibited growth of a lung squamous cell carcinoma cell line harboring a DDR2 I638F mutation in culture and in xenograft models (PMID: 22328973). | 22328973 |
| BRAF V600E | melanoma | sensitive | Dasatinib | Preclinical | Actionable | In a preclinical study, Sprycel (dasatinib) inhibited cell invasion, cell signaling, and proliferation in human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture and in animal models (PMID: 23242808). | 23242808 |
| Unknown unknown | malignant pleural solitary fibrous tumor | not applicable | Dasatinib | Phase II | Actionable | In a Phase II trial, patients with solitary fibrous tumors demonstrated a median progression free survival of 2 months and five patients demonstrated an objective tumor response when treated with Sprycel (dasatinib) (PMID: 27696380). | 27696380 |
| TET2 T1063Nfs*5 TET2 E1207K | angioimmunoblastic T-cell lymphoma | predicted - sensitive | Dasatinib | Case Reports/Case Series | Actionable | In a Phase I trial, four patients with relapsed/refractory angioimmunoblastic T-cell lymphoma harboring TET2 mutations and/or RHOA G17V achieved a partial response within 30 days of Sprycel (dasatinib) treatment, including one patient harboring TET2 T1063Nfs*5 and TET2 E1207K who maintained the partial response at the time of trial discontinuation (PMID: 32107212). | 32107212 |
| CSF3R T618I CSF3R W791* | hematologic cancer | predicted - resistant | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed hematologic cells co-expressing CSF3R T618I and CSF3R W791* were resistant to treatment with Sprycel (dasatinib) in culture (PMID: 28031554). | 28031554 |
| KIT A829P | melanoma | sensitive | Dasatinib | Preclinical | Actionable | In a preclinical study, Sprycel (dasatinib) demonstrated efficacy by inhibiting proliferation of cultured melanoma cells expressing KIT A829P (PMID: 23582185, PMID: 25594040). | 23582185 25594040 |
| KIT N822I | Advanced Solid Tumor | sensitive | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sprycel (dasatinib) inhibited growth and induced apoptosis of transformed cells expressing KIT N822I in culture (PMID: 21689725). | 21689725 |
| ABL1 R332W | lung adenocarcinoma | sensitive | Dasatinib | Preclinical | Actionable | In a preclinical study, treatment with Sprycel (dasatinib) in decreased CRKL phosphorylation and reduced viability of lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) in culture (PMID: 26758680). | 26758680 |
| DDR2 L239R | lung squamous cell carcinoma | sensitive | Dasatinib | Preclinical | Actionable | In a preclinical study, Sprycel (dasatinib) inhibited proliferation of lung squamous cell carcinoma cells harboring a DDR2 L239R mutation in culture (PMID: 22328973). | 22328973 |
| DDR2 mutant | lung squamous cell carcinoma | sensitive | Dasatinib | Preclinical | Actionable | In a preclinical study, lung squamous cell cancer cells harboring DDR2 mutations demonstrated sensitivity to Sprycel (dasatinib) in culture (PMID: 22328973). | 22328973 |
| KIT exon11 | gastrointestinal stromal tumor | predicted - sensitive | Dasatinib | Phase II | Actionable | In a Phase II clinical trial, Sprycel (dasatinib) demonstrated preliminary activity in patients with Gleevec (imatinib)-resistant gastrointestinal stromal tumor (GIST), including patients harboring KIT exon 11 mutations, with a partial response rate of 32% (15/47), median progression-free survival of 2.0 months, and overall survival of 19 months (J Clin Oncol 29: 2011 (suppl; abstr 10006)). | detail... |
| DDR2 G253C | Advanced Solid Tumor | sensitive | Dasatinib | Preclinical | Actionable | In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 G253C in culture (PMID: 22328973). | 22328973 |
| BRAF Y472C | lung non-small cell carcinoma | sensitive | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sprycel (dasatinib) induced apoptosis in non-small cell lung carcinoma cells harboring BRAF Y472C in culture (PMID: 22649091). | 22649091 |
| KIT D820Y | melanoma | sensitive | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sprycel (dasatinib) inhibited MNK pathway activation and proliferation of melanoma cell lines harboring KIT D820Y in culture (PMID: 29035277). | 29035277 |
| KIT V560G KIT D816V | mast-cell leukemia | sensitive | Dasatinib | Preclinical | Actionable | In a preclinical study, Sprycel (dasatinib) inhibited growth and induced apoptosis in a mast-cell leukemia cell line harboring both KIT V560G and KIT D816V in culture (PMID: 18024392). | 18024392 |
| KIT L576P | melanoma | sensitive | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sprycel (dasatinib) inhibited MNK pathway activation and proliferation of melanoma cell lines harboring KIT L576P in culture (PMID: 29035277). | 29035277 |
| KIT L576P | melanoma | sensitive | Dasatinib | Case Reports/Case Series | Actionable | In a clinical study, two patients with melanoma harboring KIT L576P, one who had progressed on Gleevec (imatinib), demonstrated initial clinical benefit following treatment with Sprycel (dasatinib); however, one patient progressed after 3 months, and the other patient progressed after 4 months of treatment (PMID: 19671763). | 19671763 |
| DDR2 I638F | Advanced Solid Tumor | sensitive | Dasatinib | Preclinical | Actionable | In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 I638F in culture (PMID: 22328973). | 22328973 |
| ABL1 G321L | lung adenocarcinoma | sensitive | Dasatinib | Preclinical | Actionable | In a preclinical study, treatment with Sprycel (dasatinib) in decreased CRKL phosphorylation and reduced viability of lung adenocarcinoma cells harboring ABL1 G321L (also reported as G340L) in culture (PMID: 26758680). | 26758680 |
| IDH1 R132C | intrahepatic cholangiocarcinoma | sensitive | Dasatinib | Preclinical | Actionable | In a preclinical study, Sprycel (dasatinib) inhibited growth of intrahepatic cholangiocarcinoma cells harboring IDH1 R132C in culture, and suppressed tumor growth in PDX models (PMID: 27231123). | 27231123 |
| ARID1A Q456* | colorectal cancer | sensitive | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, a colorectal cancer cell line homozygously expressing ARID1A Q456* demonstrated sensitivity to treatment with Sprycel (dasatinib) in culture (PMID: 27364904). | 27364904 |
| KIT V560D | Advanced Solid Tumor | sensitive | Dasatinib | Preclinical | Actionable | In a preclinical study, transformed cells expressing KIT V560D were sensitive to Sprycel (dasatinib) in culture (PMID: 16397263). | 16397263 |
| Unknown unknown | Ewing sarcoma of bone | not applicable | Dasatinib | Phase II | Actionable | In a Phase II clinical trial, a trial arm assessing Sprycel (dasatinib) in Ewing sarcoma patients (n=17) was suspended due to lack of drug activity (PMID: 26710211). | 26710211 |
| DDR2 S768R | lung squamous cell carcinoma | predicted - sensitive | Dasatinib | Case Reports/Case Series | Actionable | In a clinical case study, patient with lung squamous cell carcinoma harboring a DDR2 S768R mutation had a positive response to (Sprycel) dasatinib treatment (PMID: 23932362). | 23932362 |
| IDH1 mutant | lung adenocarcinoma | resistant | Dasatinib | Preclinical | Actionable | In a preclinical study, lung adenocarcinoma cells harboring IDH1 mutations were resistant to Sprycel (dasatinib) in culture (PMID: 27231123). | 27231123 |
| Unknown unknown | chronic myeloid leukemia | not applicable | Dasatinib | Clinical Study | Actionable | In a meta-analysis, Sprycel (dasatinib) treatment was associated with increased rate of major molecular response compared with Gleevec (imatinib) (Odds Ratio (OR): 2.17 [1.66-2.83]), but not improved overall survival (OR: 0.42 [0.14-1.31]), and was associated with increased risk of vascular occlusive events (OR: 3.86 [1.33-11.18]) in patients with chronic myeloid leukemia (PMID: 26847662). | 26847662 |
| CSF3R W791* | hematologic cancer | predicted - resistant | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed hematologic cells expressing CSF3R W791* demonstrated resistance to treatment with Sprycel (dasatinib) in culture (PMID: 28031554). | 28031554 |
| ABL1 T315I ABL1 R332W | lung adenocarcinoma | resistant | Dasatinib | Preclinical | Actionable | In a preclinical study, lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) and expressing ABL1 T315I demonstrated resistance to Sprycel (dasatinib) in culture (PMID: 26758680). | 26758680 |
| IDH1 R132S | intrahepatic cholangiocarcinoma | sensitive | Dasatinib | Preclinical | Actionable | In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S demonstrated increased sensitivity to Sprycel (dasatinib) induced growth inhibition compared to IDH1 wild-type cells in culture (PMID: 27231123). | 27231123 |
| Unknown unknown | leiomyosarcoma | not applicable | Dasatinib | Phase II | Actionable | In a Phase II clinical trial, 13% (6/42) of patients with leiomyosarcoma demonstrated clinical benefit with a median progression free survival of 2.2 months when treated with Sprycel (dasatinib) but were below levels considered to result from drug activity (PMID: 26710211). | 26710211 |
| Unknown unknown | sarcoma | not applicable | Dasatinib | Phase II | Actionable | In a Phase II clinical trial, 19% (8/42) of patients with undifferentiated pleomorphic sarcoma demonstrated clinical benefit when treated with Sprycel (dasatinib), however the 6 month progression free survival rate in patients was only 12% (6/42) (PMID: 26710211). | 26710211 |
| DDR2 L63V | lung squamous cell carcinoma | sensitive | Dasatinib | Preclinical | Actionable | In a preclinical study, Sprycel (dasatinib) prevented colony formation and induced cell death in lung squamous cell carcinoma cells expressing DDR2 L63V in culture (PMID: 22328973). | 22328973 |
| DDR2 L63V | Advanced Solid Tumor | sensitive | Dasatinib | Preclinical | Actionable | In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 L63V in culture (PMID: 22328973). | 22328973 |
| CSF3R S783fs | chronic neutrophilic leukemia | predicted - sensitive | Dasatinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, cells derived from a patient with chronic neutrophilic leukemia harboring CSF3R S783fs demonstrated sensitive to treatment with Sprycel (dasatinib) in culture (PMID: 23656643). | 23656643 |
| KIT D816V | hematologic cancer | sensitive | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing KIT D816V were sensitive to treatment with Sprycel (dasatinib) in culture, demonstrating reduced cell survival (PMID: 31182436). | 31182436 |
| PDGFRA amp | lung squamous cell carcinoma | sensitive | Dasatinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Sprycel (dasatinib) inhibited growth of a lung squamous cell cancer (SCC) cell line with amplification of PDGFRA in culture, and inhibited tumor growth in PDGFRA-amplified lung SCC xenograft models (PMID: 22328973). | 22328973 |
| KIT W557_K558del | Advanced Solid Tumor | sensitive | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sprycel (dasatinib) inhibited growth and induced apoptosis of transformed cells expressing KIT W557_K558del in culture (PMID: 17699867). | 17699867 |
| KIT D419del | hematologic cancer | no benefit | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing KIT D419del did not respond to treatment with Sprycel (dasatinib) in culture (PMID: 31182436). | 31182436 |
| DDR2 G774V | Advanced Solid Tumor | sensitive | Dasatinib | Preclinical | Actionable | In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing DDR2 G774V in culture (PMID: 22328973). | 22328973 |
| KIT V559D KIT D820Y | Advanced Solid Tumor | sensitive | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sprycel (dasatinib) inhibited proliferation of transformed cells expressing a KIT V559D/D820Y double mutation in culture (PMID: 17699867). | 17699867 |
| Unknown unknown | epithelioid sarcoma | not applicable | Dasatinib | Phase II | Actionable | In a Phase II trial, patients with epithelioid sarcoma demonstrated a median progression free survival of 7.9 months and two patients demonstrated an objective tumor response when treated with Sprycel (dasatinib) (PMID: 27696380). | 27696380 |
| ABL1 rearrange | myeloid neoplasm | sensitive | Dasatinib | Guideline | Actionable | Sprycel (dasatinib) is included in guidelines for patients with a myeloid/lymphoid neoplasm with eosinophilia harboring a ABL1 rearrangement (NCCN.org). | detail... |
| BRAF V600E | lung carcinoma | resistant | Dasatinib | Preclinical | Actionable | In a preclinical study, Sprycel (dasatinib) failed to induce apoptosis in lung carcinoma cells expressing BRAF V600E (PMID: 22649091). | 22649091 |
| Unknown unknown | lung non-small cell carcinoma | not applicable | Dasatinib | Phase II | Actionable | In a Phase II trial, Sprycel (dasatinib) treatment in non-small cell lung carcinoma patients showed some clinical efficacy, resulting in one patient with a partial response, and 12 patients with stable disease, demonstrating a disease control rate of 43% (13/30)(PMID: 20855820). | 20855820 |
| DDR2 L239R DDR2 T654I | lung squamous cell carcinoma | predicted - resistant | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, DDR2 T654I was identified as an acquired mutation in lung squamous cell carcinoma cells harboring DDR2 L239R that became resistant to Sprycel (dasatinib) in culture (PMID: 24296828). | 24296828 |
| KIT N822K | hematologic cancer | sensitive | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing KIT N822K were sensitive to treatment with Sprycel (dasatinib) in culture, demonstrating reduced cell survival (PMID: 31182436). | 31182436 |
| IDH1 mutant | chondrosarcoma | resistant | Dasatinib | Preclinical | Actionable | In a preclinical study, chondrosarcoma cells harboring IDH1 mutations were resistant to Sprycel (dasatinib) in culture (PMID: 27231123). | 27231123 |
| IDH1 R132C SRC T341I | intrahepatic cholangiocarcinoma | resistant | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S acquired resistance to Sprycel (dasatinib) after over expressing SRC T341I in culture (PMID: 27231123). | 27231123 |
| Unknown unknown | chondrosarcoma | not applicable | Dasatinib | Phase II | Actionable | In a Phase II trial, patients with chondrosarcoma demonstrated a median progression free survival of 5.5 months and six patients demonstrated an objective tumor response when treated with Sprycel (dasatinib) (PMID: 27696380). | 27696380 |
| KIT W557_K558del KIT T670I | Advanced Solid Tumor | resistant | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing a KIT W557_K558del/T670I double mutation demonstrated resistance to Sprycel (dasatinib) in culture (PMID: 17699867). | 17699867 |
| Unknown unknown | chordoma | not applicable | Dasatinib | Phase II | Actionable | In a Phase II trial, patients with chordoma demonstrated a median progression free survival of 6.3 months and six patients demonstrated an objective tumor response when treated with Sprycel (dasatinib) (PMID: 27696380). | 27696380 |
| SRC positive | glioblastoma | sensitive | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sprycel (dasatinib) treatment resulted in a strong antitumoral effect in GBM cell lines with high levels of Src phosphorylation (PMID: 19098899). | 19098899 |
| KIT D419G | hematologic cancer | no benefit | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing KIT D419G did not respond to treatment with Sprycel (dasatinib) in culture (PMID: 31182436). | 31182436 |
| CSF3R Q741* | hematologic cancer | predicted - resistant | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed hematologic cells expressing CSF3R Q741* demonstrated resistance to treatment with Sprycel (dasatinib) in culture (PMID: 28031554). | 28031554 |
| APC inact mut | colorectal cancer | sensitive | Dasatinib | Preclinical | Actionable | In a preclinical study, the combination of Sprycel (dasatinib) and curcumin inhibited tumor growth in a mouse model of colorectal cancer harboring an Apc mutation (PMID: 20473900). | 20473900 |
| Unknown unknown | liposarcoma | not applicable | Dasatinib | Phase II | Actionable | In a Phase II clinical trial, a trial arm assessing Sprycel (dasatinib) in liposarcoma patients (n=11) was suspended due to lack of drug activity (PMID: 26710211). | 26710211 |
| DDR2 over exp | head and neck squamous cell carcinoma | sensitive | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sprycel (dasatinib) inhibited cell migration and invasion of head and neck squamous cell carcinoma cells overexpressing Ddr2, in culture (PMID: 27434411). | 27434411 |
| PDGFRA D842V | gastrointestinal stromal tumor | sensitive | Dasatinib | Guideline | Actionable | Sprycel (dasatinib) is included in the guidelines for patients with gastrointestinal stromal tumor (GIST) with PDGFRA D842V mutations (NCCN.org). | detail... |
| PDGFRA D842V | gastrointestinal stromal tumor | sensitive | Dasatinib | Phase 0 | Actionable | In a clinical trial, Sprycel (dasatinib) treatment resulted in a partial response in 25% (12/48) of patients with Gleevec (imatinib)-resistant gastrointestinal stromal tumor, with decreased tumor size in 2 of those patients, 1 of which harbored PDGFRA D842V (PMID: 29710216). | 29710216 |
| KIT V559D | Advanced Solid Tumor | sensitive | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sprycel (dasatinib) decreased KIT signaling, and inhibited growth and induced apoptosis of transformed cells expressing KIT V559D in culture (PMID: 21689725). | 21689725 |
| Unknown unknown | rhabdomyosarcoma | not applicable | Dasatinib | Phase II | Actionable | In a Phase II clinical trial, a trial arm assessing Sprycel (dasatinib) in rhabdomyosarcoma patients (n=13) was suspended due to lack of drug activity (PMID: 26710211). | 26710211 |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04530565 | Phase III | Cyclophosphamide + Dasatinib + Dexamethasone + Doxorubicin + Vincristine Sulfate Blinatumomab + Dexamethasone + Ponatinib + Prednisone Blinatumomab + Dasatinib + Dexamethasone + Prednisone Dasatinib Ponatinib Blinatumomab + Dexamethasone + Methotrexate + Ponatinib + Prednisone Blinatumomab + Dasatinib + Dexamethasone + Methotrexate + Prednisone Ponatinib + Prednisone Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Mesna + Methotrexate + Vincristine Sulfate Cytarabine + Methotrexate + Ponatinib Cytarabine + Dasatinib + Methotrexate Cyclophosphamide + Dexamethasone + Doxorubicin + Ponatinib + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Doxorubicin + Methotrexate + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Ponatinib + Vincristine Sulfate Dasatinib + Prednisone | Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults | Recruiting | USA | 0 |
| NCT01652976 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Dasatinib | Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma | Completed | USA | 0 |
| NCT01256398 | Phase II | Dexamethasone Dasatinib Tacrolimus Cyclophosphamide + Fludarabine Filgrastim Mercaptopurine + Methotrexate + Vincristine Sulfate Melphalan Cytarabine + Daunorubicin + Etoposide Pegfilgrastim Alemtuzumab Leucovorin | Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | Active, not recruiting | USA | 0 |
| NCT02465060 | Phase II | Erdafitinib Copanlisib Trametinib Crizotinib Sunitinib Sapanisertib Nivolumab AZD4547 Dasatinib Pertuzumab + Trastuzumab Dabrafenib + Trametinib Binimetinib Adavosertib Osimertinib Palbociclib Afatinib Capivasertib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Larotrectinib Taselisib | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | Recruiting | USA | 2 |
| NCT01876212 | Phase II | Dasatinib | Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma | Completed | USA | 0 |
| NCT01990196 | Phase II | Dasatinib Trametinib Degarelix + Enzalutamide | Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer | Active, not recruiting | USA | 0 |
| NCT03878524 | Phase I | Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab | A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) | Recruiting | USA | 0 |
| NCT02720185 | Phase II | Dasatinib | Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR | Recruiting | USA | 0 |
| NCT04115059 | Phase I | Dasatinib | Dasatinib In Waldenstrom Macroglobulinemia | Recruiting | USA | 0 |
| NCT01514864 | Phase II | Dasatinib | Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation | Terminated | USA | CAN | 5 |
| NCT02059265 | Phase II | Dasatinib | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer | Active, not recruiting | USA | 0 |
| NCT02709083 | Phase II | Dasatinib Nilotinib Imatinib | Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia | Terminated | USA | 0 |
| NCT02559778 | Phase I | Bortezomib Crizotinib Lapatinib Vorinostat Eflornithine Sorafenib Dasatinib | Pediatric Precision Laboratory Advanced Neuroblastoma Therapy | Recruiting | USA | 0 |
| NCT01244750 | Phase I | Imatinib Dasatinib Nilotinib | Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting | Unknown status | USA | 7 |
| NCT00918463 | Phase II | Dasatinib | A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Terminated | USA | 0 |
| NCT02779283 | Phase I | Dasatinib Nilotinib Ponatinib Sorafenib Cytarabine + Idarubicin Sunitinib | Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Completed | USA | 0 |
| NCT01445509 | Phase I | Bevacizumab Dasatinib | Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors | Completed | USA | 0 |
| NCT02268370 | Phase II | Dasatinib | Treatment-free Remission Accomplished With Dasatinib in Patients With CML (TRAD) | Active, not recruiting | CAN | 0 |
| NCT00700882 | Phase II | Dasatinib | Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery | Active, not recruiting | USA | 0 |
| NCT00608361 | Phase I | Dasatinib | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | Completed | USA | 0 |
| NCT01850004 | Phase II | Dasatinib | Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response | Active, not recruiting | USA | CAN | 4 |
| NCT03654768 | Phase II | Bosutinib Dasatinib Nilotinib Dasatinib + Ruxolitinib Bosutinib + Ruxolitinib Nilotinib + Ruxolitinib | Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia | Recruiting | USA | 0 |
| NCT02015728 | Phase I | Erlotinib Everolimus Dasatinib Etoposide + Temozolomide Sorafenib | Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors | Unknown status | USA | 0 |
| NCT01593254 | Phase II | Imatinib Dasatinib | Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN) | Active, not recruiting | USA | CAN | 13 |
| NCT01609816 | Phase Ib/II | Dasatinib | Dasatinib in Treating Patients With Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated With Autologous Stem Cell Transplant | Terminated | USA | 0 |
| NCT03117751 | Phase II | Cyclophosphamide Vincristine Sulfate Idarubicin Blinatumomab Doxorubicin Clofarabine Vorinostat Ruxolitinib Prednisone Bortezomib Etoposide Dasatinib Daunorubicin Dexamethasone Rituximab Methotrexate Cytarabine Mercaptopurine Pegaspargase | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | Recruiting | USA | 0 |
| NCT01471106 | Phase II | Dasatinib | Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer | Active, not recruiting | USA | 0 |
| NCT00777036 | Phase II | Dasatinib | A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib | Active, not recruiting | USA | CAN | 16 |
| NCT02428855 | Phase II | Dasatinib | Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma | Completed | USA | 0 |
| NCT01482728 | Phase I | Dasatinib | Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer | Completed | USA | 0 |
| NCT01441882 | Phase II | Dasatinib | A Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity | Completed | USA | 0 |
| NCT02551718 | Phase I | Bosutinib Irinotecan Romidepsin Busulfan Melphalan Nilotinib Crizotinib Cytarabine Mitoxantrone Dasatinib Pazopanib Paclitaxel Clofarabine Hydroxyurea Tretinoin Carfilzomib Nelarabine Bexarotene Pentostatin Everolimus Cabozantinib Mercaptopurine Methotrexate Cladribine Thioguanine Daunorubicin Ponatinib Etoposide Afatinib Gefitinib Gemcitabine Regorafenib Arsenic trioxide Trametinib Imatinib Erlotinib Dabrafenib Decitabine Axitinib Azacitidine Ruxolitinib Fludarabine Lapatinib Ceritinib Sirolimus Sorafenib Lomustine Sunitinib Cabazitaxel Temsirolimus Topotecan Bortezomib Pralatrexate | High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia | Active, not recruiting | USA | 0 |
| NCT02043587 | Phase II | Rituximab Pegaspargase Methotrexate Cytarabine Leucovorin Cyclophosphamide Dasatinib Daunorubicin Vincristine Sulfate Etoposide | Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma | Active, not recruiting | USA | 0 |
| NCT01620216 | Phase II | Sunitinib Dasatinib Nilotinib Ponatinib Sorafenib | Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients | Terminated | USA | 0 |
| NCT00892190 | Phase I | Dasatinib | Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome | Completed | USA | 0 |
| NCT00549848 | Phase III | Daunorubicin + Pegaspargase + Vincristine Sulfate Cytarabine Mercaptopurine Thioguanine Clofarabine + Cyclophosphamide + Etoposide Methotrexate Dasatinib Doxorubicin Dexamethasone | Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | Completed | USA | 0 |
| NCT02883049 | Phase III | Dasatinib Dexamethasone + Doxorubicin Prednisone Vincristine Sulfate Thioguanine Cytarabine Mercaptopurine Leucovorin Methotrexate Pegaspargase Etoposide Clofarabine | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations | Active, not recruiting | USA | CAN | 5 |
| NCT03023046 | Phase II | Rituximab Doxorubicin Etoposide Imatinib Dasatinib Cyclophosphamide Prednisone Vincristine Sulfate | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Recruiting | USA | 0 |
| NCT03297606 | Phase II | Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) | Recruiting | CAN | 0 |
| NCT03020030 | Phase III | Nelarabine Dexrazoxane Asparaginase Vincristine Sulfate Cyclophosphamide Cytarabine Mercaptopurine Pegaspargase Methotrexate Etoposide Doxorubicin Dexamethasone Prednisone Dasatinib Leucovorin | Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | Recruiting | USA | CAN | 0 |
| NCT01643603 | Phase Ib/II | Dasatinib | Dasatinib in Treating Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | Terminated | USA | 0 |
| NCT01685125 | Phase II | Dasatinib Abiraterone | Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Unknown status | USA | 0 |
| NCT01660906 | Phase III | Dasatinib | This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib | Completed | USA | 4 |
| NCT02788201 | Phase II | Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | Completed | USA | 0 |
| NCT01015222 | Phase I | Methylnaltrexone Bromide Dasatinib Paclitaxel Bevacizumab | Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies | Active, not recruiting | USA | 0 |
| NCT02420717 | Phase II | Ruxolitinib Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Sulfate Dasatinib Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Cytarabine + Leucovorin + Methotrexate | Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia | Completed | USA | 0 |
CKB BOOST